Physician-Scientist |Cancer prevention,Precision Oncology & Genomics |Board Dir. @ICGA_india | Founder @CHIPfoundation| Fmr.Dir. @icmr_nicpr & WHOIARC @GKH_SLT
🇮🇳
Joined February 2011
- Tweets7.2K
- Following744
- Followers2.8K
- Likes3.8K
Thank you for the encouraging updates. @agingroy
Liver and gallbladder cancers, in particular, have historically been associated with some of the least favourable outcomes.
Five cancer trial readouts from ESMO 2026 stand out this week, ranked by how much they cut the risk of death.
Each one went head-to-head with today's standard in its own patients, so treat each row as its own story.
1) Divarasib, a daily pill for lung cancer with the KRAS G12C gene change, after earlier treatment. It cut the risk of death by 44% versus sotorasib or adagrasib, the two pills already approved for it. Median survival was about 18 months versus 12. Phase 3 trial, 338 patients.
2) Durvalumab plus enfortumab vedotin around bladder removal, for bladder cancer in the muscle wall in people who cannot or will not have cisplatin chemo. It cut the risk of death by 42% versus surgery with usual care. At two years, 78% were alive versus 69%. Phase 3 trial, 462 patients in this comparison.
3) Osimertinib (Tagrisso) plus savolitinib, two pills, for EGFR lung cancer that kept growing on osimertinib because of a second gene, MET. It cut the risk of death by 32% versus chemo. Median survival was about 18 months versus 13. Phase 3 trial, 338 patients.
4) Sacituzumab tirumotecan (sac-TMT), an antibody that delivers a chemo drug into cancer cells, for womb lining (endometrial) cancer that kept growing after platinum chemo and an immunotherapy. It cut the risk of death by 32% versus chemo. Median survival was 19 months versus 12. Phase 3 trial, 776 patients.
5) Ivonescimab plus chemo as first treatment for advanced bile duct or gallbladder cancer. It cut the risk of death by 25% versus durvalumab plus the same chemo, today's standard. Median survival was about 15 months versus 12. Phase 3 trial, 682 patients, run in China.
Big picture: two of the biggest lung wins only work when tumor testing finds the gene they target. In lung cancer, ask whether the tumor was tested for KRAS and MET.
2/4: Tuesday Thoughts: Early detection is important
and saves lives.
Whether it’s routine screenings, listening to your body, or checking in on your mental health, catching things early makes all the difference.
Don't put off what you can check today until tomorrow.
What’s one healthy habit you’re prioritizing this week?
#TuesdayThoughts #HealthFirst #Wellness #EarlyDetection
1/4 Monday musings: While changing lifestyle choices can be challenging, focusing on the "low-hanging fruits" of cancer prevention makes a massive impact. From tobacco control and HPV vaccination to maintaining a healthy diet and reducing harmful exposures, prevention truly is the first step. @chipfoundation
What lifestyle change do you think is the hardest to adopt, but worth the effort?
#CancerPrevention #PublicHealth #HealthyLifestyle #PreventionSavesLives
The success of the personalized mRNA vaccine is good news for patients with melanoma - hope more cancers follow.
A new personalized mRNA vaccine for melanoma is being hailed by some oncologists as a breakthrough after reducing the risk of cancer recurrence and death by 42% compared with standard treatment in a late-stage clinical trial. nbcnews.com/health/cancer/pe…
The developing world’s cancer burden: practical solutions needed , not just statistics.
The way forward requires action across the entire cancer care continuum:
Prevent: Control tobacco use and expand HPV vaccination.
Detect early: Build awareness, expand evidence-based screening, and speed diagnosis.
Make treatment affordable: Stronger public coverage, transparent pricing and access to essential medicines.
Bring care closer: Strengthen district services and referral networks.
Support beyond treatment: Rehabilitation, palliative care, mental-health support and survivorship plans.
Cancer care must be timely, affordable and continuous, not a financial crisis for families.
What should we prioritise first? Join the conversation.
#CancerCare #CancerControl #PublicHealth #India
Your chair might be raising your cancer risk!
'Emerging research suggests extended sedentary time, in and of itself, could increase certain cancer risks -regardless of your weight or physical activity level.'
Sitting for hours may be quietly raising cancer risk — even if you exercise. A large 2015 ACS study of 77,000+ women found those who sat ≥6 hours a day had a 10% higher risk of any cancer (and invasive breast cancer) than women who sat under 3 hours. The link held after accounting for body weight and physical activity.
Observational study for now, but highly plausible
washingtonpost.com/wellness/…
Not many people know that life beyond cancer is about more than follow-up visits. It means continued care, emotional support, rehabilitation, healthy living and staying connected.
Every survivor deserves the support to live well, not just longer. What are your thoughts on this?
#CancerSurvivorship #CancerCare #LifeBeyondCancer #India
'A comprehensive personal health agent that reasons over multimodal data from consumer wellness devices and medical records to provide personalized health support.' nature.com/articles/s41586-0…
Why does the time of day you get immunotherapy matter?
Early studies suggested morning infusions drastically improve survival for cancer patients. But the field still lacks definitive randomized evidence—and a recent major retraction highlights why.
The Catch with Retrospective Data
•Frailty Bias: Healthier patients get morning slots; frailer patients often face delays into the afternoon.
•Drug Half-Life: Immune checkpoint inhibitors stay active in the body for weeks. Does the exact hour of infusion really change the long-term outcome?
The Randomized Reality
•Major Retraction: The phase III LungTIME-C01 trial initially showed a massive advantage for morning dosing but was retracted in June 2026 due to protocol and data discrepancies.
•Conflicting Data: Large pooled analyses (like i-TIMES) show no meaningful survival difference between early and late infusions.
•Logistics: Standardizing morning-only dosing would create massive bottlenecks in oncology clinics worldwide.
Chronotherapy holds immense biological promise, but we need bulletproof, prospective randomized trials before rewriting clinical guidelines.
#CancerResearch #Immunotherapy #Oncology #MedEd
Time-of-Day Immunotherapy: Why the Field Still Needs Randomized Evidence | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
DYK? Facial imaging and AI could work together for predicting cancer outcomes.
Researchers have developed an AI model, FAHR-FaceSurvival, that analyses facial images to estimate mortality risk in people with cancer.
The model builds on AI-based biological age estimation, potentially detecting subtle features associated with ageing and physical resilience that may not be apparent to the naked eye.
Could this non-invasive approach one day help clinicians personalise cancer treatment?
Promising science—but not yet ready for routine clinical use. Further validation across diverse populations is essential to establish accuracy, fairness and clinical value.
#CancerResearch #ArtificialIntelligence #DigitalHealth #PrecisionOncology
There's a lot in a face photograph about health that AI can detect, as seen in this foundation model of >40 million face images, including outcomes from cancer, biological age, influence of lifestyle factors, and survival @LancetDigitalH
thelancet.com/journals/landi…
AI & Digital Pathways: Making Technology Work for Everyone
AI is transforming how we live, work and access services. But the real opportunity lies not just in adopting technology, but in making it accessible, trusted and meaningful for everyone.
The future of digital transformation must be inclusive, human-centred and driven by real-world impact.
#AI #DigitalTransformation #DigitalInclusion #Innovation #India
NEW Review: Digital pathology, image analysis, and #ArtificialIntelligence in liver disease.
Read it here: thelancet.com/journals/landi…
Wednesday Myth Buster | Survivor’s Solitude, Voices of Support
MYTH: Once cancer treatment ends, survivors can return to normal life.
REALITY: After treatment, survivors may face ongoing health concerns, workplace barriers, emotional distress, and isolation. They need support—not just sympathy.
Cancer survivorship is about more than surviving. It’s about living with dignity, confidence, and connection.
Let’s make cancer survivor support programs a priority in hospitals, workplaces, and communities. Share this post and help amplify survivors’ voices.
#MondayMythBuster #CancerSurvivorship #CancerCare #SurvivorSupport.
Tuesday Myth Buster | Survivor’s Solitude, Voices of Support
MYTH: Once cancer treatment ends, survivors return to normal life.
REALITY: The end of treatment doesn't always mean the end of challenges. Survivors may face ongoing health concerns, workplace barriers, emotional distress, and isolation.
Cancer survivorship is more than survival—it’s about living with dignity, confidence, and support.
Let’s make survivor support programs a priority in hospitals, workplaces, and communities. Share this post and help amplify survivors’ voices.
#MondayMythBuster #CancerSurvivorship #CancerCare #SurvivorSupport
